CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM034258
Első szerző:Garami Zoltán (orvos)
Cím:The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan / Garami Zoltán, Hascsi Zsolt, Varga József, Dinya Tamás, Tanyi Miklós, Garai Ildikó, Damjanovich László, Galuska László
Dátum:2012
ISSN:0748-7983
Megjegyzések:Proper preoperative staging is vital in the treatment of breast cancer patients. The aim of our study was to assess the value of the diagnostic information provided by PET/CT in surgical practice in breast cancer cases considered early-stage by conventional diagnostic modalities. METHODS: Whole-body 18-FDG PET/CT was performed on 115 breast cancer patients in whom traditional diagnostic modalities showed no signs of distant metastases or extensive axillary and/or extra-axillary lymphatic spreading, and the size of the primary tumor was <4 cm. RESULTS: The sensitivity of PET/CT in the detection of the primary tumor was 93%. The sensitivity of the traditional diagnostic modalities in the detection of multifocality was 43.8% while that of PET/CT was 100% (p < 0.001). In the assessment of axillary lymph nodes, ultrasound had a sensitivity of 30% and a specificity of 95%. The corresponding estimates for PET/CT were 72% and 96%, respectively. PET/CT detected distant metastases in 8 patients. TNM classification was modified after PET/CT scanning in 54 patients (47%). PET/CT data changed the treatment plan established upon the results of traditional imaging modalities in 18 patients (15.6%). CONCLUSIONS: PET/CT is able to assess primary tumor size and axillary lymphatic status more accurately than traditional diagnostic methods. It can detect distant metastases in 7-8% of those patients who were declared free of metastasis by clinical investigations. PET/CT scan modifies the disease stage determined by traditional diagnostic modalities in almost half of the patients and leads to a change in the treatment plan in every 6th patient.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:European Journal of Surgical Oncology. - 38 : 1 (2012), p. 31-37. -
További szerzők:Hascsi Zsolt Varga József (1955-) (fizikus) Dinya Tamás (1974-) (sebész szakorvos, onkológus szakorvos) Tanyi Miklós (1968-) (sebész) Garai Ildikó (1966-) (radiológus) Damjanovich László (1960-) (általános sebész) Galuska László (1946-) (belgyógyász, izotópdiagnoszta)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM056494
Első szerző:Tanyi Miklós (sebész)
Cím:MLH1 and MSH2 mutation screening in HNPCC families of Hungary - Two new MMR gene mutations / M. Tanyi, J. Olasz, J. L. Tanyi, L. Tóth, P. Antal-Szalmás, Z. Ress, T. Bubán, K. Palatka, C. András, H. Urbancsek, Z. Garami, O. Csuka, L. Damjanovich
Dátum:2014
Megjegyzések:Hereditary Non-Polyposis Colorectal Cancer is an inherited disease with deleterious germline mutations in the DNA mismatch repair genes causing the development of colon cancer and other malignancies. This is the first study in Hungary screening the population of our colorectal cancer patients in order to identify the prevalence of the disease. METHODS: In families who met the Modified Amsterdam and Bethesda Criteria the removed tumor tissue was first examined by immunohistochemistry and microsatellite instability analysis. Those cases which showed high microsatellite instability underwent DNA sequencing and multiple ligation dependent probe amplification. RESULTS: Of the 1576 patients with colorectal cancer underwent screening for the modified Amsterdam and Bethesda criteria, 69 (4.4%) and 166 (10.5%) fulfilled the criteria respectively. 15 patients (31%) of the Amsterdam positive group and 19 patients from the Bethesda positive (18.1%) were MSI-H. There were 8 pathogenic mutations identified in 9 families (60%) in the Amsterdam positive group. 5 mutations were found in 5 families (26%) in the Bethesda positive group. 12 pathogenic mutations were identified, two of these are newly identified, and being published first in this work. These two new mutations were located on MLH1 (g.31276_35231del) and MSH2 (c.969_970delTC) genes. CONCLUSION: The prevalence of the mutations in the MLH1 and MSH2 genes was almost equal in our Hungarian colorectal cancer patients. One mutation in the MLH1 gene (c.143A > C; p.Q48P) was identified in three different families. Whether this mutation is the most frequent in the Hungarian population is still unidentified and warrant further investigation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:European Journal of Surgical Oncology . - 40 : 11 (2014), p. 1445-1452. -
További szerzők:Olasz J. (Budapest) Tanyi János L. Tóth László (1971-) (patológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Ress Zsuzsa (1976-) (belgyógyász) Bubán Tamás (1967-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) András Csilla (1961-) (onkológus szakorvos) Urbancsek Hilda (1966-) Garami Zoltán (1963-) (orvos) Csuka Orsolya Damjanovich László (1960-) (általános sebész)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1